In an era of widespread genetic sequencing, the ability to edit and alter an organism’s DNA is a powerful way to explore the information within and how it guides biological function.
A paper from the University of Wisconsin-Madison in the August issue of the journal GENETICS takes genome editing to a new level in fruit flies, demonstrating a remarkable level of fine control and, importantly, the transmission of those engineered genetic changes across generations.
Both features are key for driving the utility and spread of an approach that promises to give researchers new insights into the basic workings of biological systems, including embryonic development, nervous system function, and the understanding of human disease.
“Genome engineering allows you to change gene function in a very targeted way, so you can probe function at a level of detail” that wasn’t previously possible, says Melissa Harrison, an assistant professor of biomolecular chemistry in the UW-Madison School of Medicine and Public Health and one of the three senior authors of the new study.
Disrupting individual genes has long been used as a way to study their roles in biological function and disease. The new approach, based on molecules that drive a type of bacterial immune response, provides a technical advance that allows scientists to readily engineer genetic sequences in very detailed ways, including adding or removing short bits of DNA in chosen locations, introducing specific mutations, adding trackable tags, or changing the sequences that regulate when or where a gene is active.
The approach used in the new study, called the CRISPR RNA/Cas9 system, has developed unusually fast. First reported just one year ago by scientists at the Howard Hughes Medical Institute and University of California, Berkeley, it has already been applied to most traditional biological model systems, including yeast, zebrafish, mice, the nematode C. elegans, and human cells. The Wisconsin paper was the first to describe it in fruit flies and to show that the resulting genetic changes could be passed from one generation to the next.
“There was a need in the community to have a technique that you could use to generate targeted mutations,” says Jill Wildonger, a UW-Madison assistant professor of biochemistry and another senior author of the paper. “The need was there and this was the technical advance that everyone had been waiting for.”
“The reason this has progressed so quickly is that many researchers — us included — were working on other, more complicated, approaches to do exactly the same thing when this came out,” adds genetics assistant professor Kate O’Connor-Giles, the third senior author. “This is invaluable for anyone wanting to study gene function in any organism and it is also likely to be transferable to the clinical realm and gene therapy.”
The CRISPR RNA/Cas9 system directs a DNA-clipping enzyme called Cas9 to snip the DNA at a targeted sequence. This cut then stimulates the cell’s existing DNA repair machinery to fill in the break while integrating the desired genetic tweaks. The process can be tailored to edit down to the level of a single base pair — the rough equivalent of changing a single letter in a document with a word processor.
The broad applicability of the system is aided by a relatively simple design that can be customized through creation of a short RNA sequence to target a specific sequence in the genome to generate the desired changes. Previous genome editing methods have relied on making custom proteins, which is costly and slow.
“This is so readily transferable that it’s highly likely to enable gene knockout and other genome modifications in any organism,” including those that have not previously been used for laboratory work, says O’Connor-Giles. “It’s going to turn non-model organisms into genetic model organisms.”
That ease may also pay off in the clinic. “It can be very difficult and time-consuming to generate models to study all the gene variants associated with human diseases,” says Wildonger. “With this genome editing approach, if we work in collaboration with a clinician to find [clinically relevant] mutations, we can rapidly translate these into a fruit fly model to see what’s happening at the cellular and molecular level.”
The Latest on: Genome editing
- Sangamo Therapeutics : Announces Treatment of First Patient in Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing for MPS II on November 21, 2017 at 12:52 pm
"For the first time, a patient has received a therapy intended to precisely edit the DNA of cells directly inside the body. We are at the start of a new frontier of genomic medicine," said Dr. Sandy Macrae, CEO of Sangamo Therapeutics. Sangamo aims to ... […]
- Genome editing/genome engineering market worth 6.28 billion USD by 2022 according to new research report on November 21, 2017 at 11:54 am
According to a new market research report "Genome Editing/Genome Engineering Market by Technology (CRISPR, TALEN, ZFN), Application (Cell Line Engineering, Animal Genetic Engineering, Plant Genetic Engineering), End User (Biotechnology & Pharmaceutical ... […]
- Genome Editing/Genome Engineering Market Worth 6.28 Billion USD by 2022 on November 20, 2017 at 5:37 am
CRISPR to account for the largest technology segment in the genome editing/genome engineering market in 2017 The technology segment of the Genome Editing Market is classified into CRISPR, TALEN, ZFN, antisense, and other technologies (PiggyBac, Flp-In ... […]
- Genome editing, metaphors and language choices on November 17, 2017 at 12:00 am
Genetic Alliance and the Progress Educational Trust recently published a report entitled ‘’Basic understanding of genome editing”, based on research supported by the Wellcome Trust. As I have worked on metaphors relating to genetic, genomics and ... […]
- A New and Improved Genome Editing Tool on November 16, 2017 at 6:39 pm
Since the development of a genome-editing tool called CRISPR/Cas9, scientists have been seeking to refine and improve it. Inspired by physiological tools used by bacteria, the gene editor can change genes in many ways and is able to excise pieces of DNA or ... […]
- Sangamo Genome Editing Trial, Assessing MPS II Candidate, Treats First Patient on November 15, 2017 at 12:00 am
Sangamo Therapeutics said today it has treated the first patient in the Phase I/II CHAMPIONS clinical trial assessing its in vivo genome-editing candidate therapy SB-913 for mucopolysaccharidosis type II (MPS II), also called Hunter syndrome. “We are at ... […]
- Sangamo Announces Treatment Of First Patient In Landmark Phase 1/2 Clinical Trial Evaluating In Vivo Genome Editing For MPS II on November 14, 2017 at 9:10 pm
RICHMOND, Calif., Nov. 15, 2017 /PRNewswire/ -- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced treatment of the first patient in the Phase 1/2 clinical trial (" the CHAMPIONS study") evaluating SB-913, an investigational in vivo genome editing ... […]
- CRISPR-carrying nanoparticles edit the genome on November 13, 2017 at 9:25 pm
In a new study, MIT researchers have developed nanoparticles that can deliver the CRISPR genome-editing system and specifically modify genes, eliminating the need to use viruses for delivery. Credit: MIT In a new study, MIT researchers have developed ... […]
via Google News and Bing News